Abstract Highlighting New Data from the Iomab-B Pivotal Phase 3 SIERRA Trial to be Presented at 2019 ASCO Annual Meeting
NEW YORK, May 16, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that an abstract pertaining to its lead product candidate, Iomab-B, which is being studied in the pivotal Phase 3 SIERRA study, will be presented via poster at the 2019 ASCO or American Society of Clinical Oncology Annual Meeting that is being held from May 31st – June 4th at McCormick Place, in Chicago. The data to be presented at ASCO is a new analysis from the first 25% of patients enrolled in the SIERRA trial highlighting that by day 3 after Iomab-B administration, patients had a 98% median reduction in peripheral blasts and 100% reduction in blasts by day 8. This significant and rapid reduction in blasts occurred with patients receiving only a single therapeutic infusion of Iomab-B and no other pre-transplant conditioning. As a result, patients had significantly lower circulating leukemia burden prior to their BMT or Bone Marrow Transplant with all patients that received a therapeutic infusion of Iomab-B having robust engraftment despite active disease prior to Iomab-B conditioning.
News 
Market Data 
Discover 
